Prelude Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-8,778
| Closed | -$486K | – | 1387 |
|
|
2024
Q4 | $486K | Sell |
8,778
-4,622
| -34% | -$256K | 0.03% | 511 |
|
|
2024
Q3 | $441K | Buy |
+13,400
| New | +$441K | 0.03% | 604 |
|
|
2024
Q2 | – | Sell |
-15,200
| Closed | -$553K | – | 1394 |
|
|
2024
Q1 | $553K | Sell |
15,200
-4,800
| -24% | -$174K | 0.03% | 530 |
|
|
2023
Q4 | $405K | Buy |
+20,000
| New | +$405K | 0.03% | 521 |
|
|
2023
Q2 | – | Sell |
-17,365
| Closed | -$218K | – | 1246 |
|
|
2023
Q1 | $218K | Sell |
17,365
-1,200
| -6% | -$15.1K | 0.01% | 732 |
|
|
2022
Q4 | $272K | Buy |
18,565
+1,744
| +10% | +$25.6K | 0.01% | 717 |
|
|
2022
Q3 | $288K | Sell |
16,821
-2,228
| -12% | -$38.1K | 0.01% | 870 |
|
|
2022
Q2 | $278K | Buy |
+19,049
| New | +$278K | 0.01% | 940 |
|